Search research articles
Contact Us
Filters
Showing results (281-290 of 418) with videos related to
Page
of 42
Sort By:
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
JAAD International
|
March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Xue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Nature Communications
|
August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2012
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
Chengwen Liu, Weiyi Peng, Chunyu Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Dennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
Nature Communications
|
February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
Cell
|
September 12, 2015
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel, Christian Posch, Steven R Barthel, et al.
Page
of 42
Search research articles
Search
Showing results (281-290 of 418) with videos related to
Sort By:
Page
of 42
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
JAAD International
|
March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Xue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Nature Communications
|
August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2012
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
Chengwen Liu, Weiyi Peng, Chunyu Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Dennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
Nature Communications
|
February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
Cell
|
September 12, 2015
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel, Christian Posch, Steven R Barthel, et al.
Page
of 42